Gilead Sciences trades near multi-year lows after a Q1 earnings miss and questions regarding product sales.
The company is utilizing the stock declines and large cash flows to repurchase shares at a fast clip.
The stock now offers one of the highest net payout yields in the market.
One of the surprise outcomes of the recent decline in biotech stock prices are the yields that some of these stocks now offer. Gilead Sciences (NASDAQ:GILD) is one of the more interesting yield plays as the dividend yield is roughly 2.3%, but the stock buybacks signal a larger value proposition.